Other: — Other:
Part of: 2933 — Heterocyclic compounds with nitrogen hetero-atom(s) only:
N305182 · 2019-07-26 — The tariff classification of Chemical Intermediates from Ireland and China
The products are as follows: Item 1 The first product, “Chemical A,” is a proprietary, separate intermediate organic chemical compound in the synthesis of an experimental Alzheimer’s drug in Phase III clinical trials. The country of origin is Ireland. This compound will be imported in noncommercial quantities and will be used solely for quality control testing. The applicable subheading for the advanced intermediate compound, “Chemical A,” will be 2935.90.7500, Harmonized Tariff Schedule of the United States (HTSUS), which provides for: Sulfonamides: Other: Other: Other: Products described in…
W563169 · 2007-08-31 — Protest AFR No. 3195-04-100142; Polypeptides; 9817.85.01 Prototype Treatment; Additional U.S. Rule of Interpretation 1(b); Actual Use; 19 CFR 10.134; Classification
This is our decision on the application for further review (AFR) of protest no. 3195-04-100142, timely filed against your classification of polypeptides, under the Harmonized Tariff Schedule of the United States (HTSUS). Our decision follows a teleconference held on June 8, 2005, between counsel for the protestant, American Peptide Company, Inc. (APC) and members of the staff of the Office of Regulations and Rulings, Tariff Classification and Marking Branch and Valuation and Special Programs Branch. We have granted the protestant’s request for confidentiality for the structural formulas and…
N011563 · 2007-05-23 — The tariff classification of Telaprevir (VX-950) (CAS- 402957-28-2), imported in both bulk and dosage forms, from Portugal
The subject product, Telaprevir, is a protease inhibitor (PI) for the treatment of hepatitis C virus (HCV) infection. You state that Vertex has initiated a Phase 2b clinical trial in the United States to evaluate sustained viral response rates in treatment-naïve patients with genotype-1 HCV. Vertex is also conducting a Phase 2b trial in patients with genotype-1 HCV who have not achieved a sustained viral response with previous interferon-based treatment. You suggest that Telaprevir in bulk is classifiable in subheading 2924.29. We respectfully disagree. In its structure, Telaprevir contains a…
M82969 · 2006-05-04 — The tariff classification of RSD1235 (CAS-748810-28-8), imported in bulk form, from Switzerland
, you requested a tariff classification ruling. The subject product, RSD1235, is an investigational new drug for the treatment of atrial fibrillation. A press release dated March 31, 2006 announced that your client has submitted a New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA), in order to gain approval to market an intravenous formulation containing RSD1235 as the active ingredient. You assert that the proper tariff classification for RSD1235 is subheading 2942.00.0500, HTSUS, which provides for “Other organic compounds: Aromatic or modified aromatic: Other: Drugs.”…
L80608 · 2004-11-02 — The tariff classification of Bortezomib (CAS-179324-69-7), imported in bulk form, and VELCADE® (bortezomib) for Injection, from Canada and the United Kingdom
, you requested a tariff classification ruling. Bortezomib is an antineoplastic agent indicated for the treatment of multiple myeloma (a cancer of the plasma cell) patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy. VELCADE® (bortezomib) for Injection is a sterile, lyophilized powder, put up in single-dose vials (3.5 mg per vial), containing bortezomib as the active ingredient. You propose that Bortezomib, when imported in bulk form, should be classified under heading 2931, HTS, within subheading 2931.00.2200, HTS, which…
Not sure this code fits your product? HaiLang AI determines the US HTS code from a description in about a minute.
Classify a product